Department of Obstetrics and Gynecology, Shengjing Hospital of China Medical University, Shenyang, China.
Department of General Surgery, General Hospital of Northern Theater Command, Shenyang, China.
Biomed Pharmacother. 2023 Aug;164:114909. doi: 10.1016/j.biopha.2023.114909. Epub 2023 May 19.
Endometriosis (EM) is characterized by the existence of endometrial mucosa outside the uterine cavity, which causesinfertility, persistent aches, and a decline in women's quality of life. Both hormone therapies and nonhormone therapies, such as NSAIDs, are ineffective, generic categories of EM drugs. Endometriosis is a benign gynecological condition, yet it shares a number of features with cancer cells, including immune evasion, survival, adhesion, invasion, and angiogenesis. Several endometriosis-related signaling pathways are comprehensively reviewed in this article, including E2, NF-κB, MAPK, ERK, PI3K/Akt/mTOR, YAP, Wnt/β-catenin, Rho/ROCK, TGF-β, VEGF, NO, iron, cytokines and chemokines. To find and develop novel medications for the treatment of EM, it is essential to implicitly determine the molecular pathways that are disordered during EM development. Additionally, research on the shared pathways between EM and tumors can provide hypotheses or suggestions for endometriosis therapeutic targets.
子宫内膜异位症（EM）的特征是子宫内膜组织出现在子宫腔以外的部位，导致不孕、持续疼痛和女性生活质量下降。激素治疗和非激素治疗（如 NSAIDs）都无效，是 EM 药物的通用类别。子宫内膜异位症是一种良性妇科疾病，但它与癌细胞有许多共同特征，包括免疫逃避、存活、黏附、侵袭和血管生成。本文全面综述了几种与子宫内膜异位症相关的信号通路，包括 E2、NF-κB、MAPK、ERK、PI3K/Akt/mTOR、YAP、Wnt/β-catenin、Rho/ROCK、TGF-β、VEGF、NO、铁、细胞因子和趋化因子。为了寻找和开发治疗 EM 的新药，必须明确确定 EM 发展过程中失调的分子途径。此外，对 EM 和肿瘤之间共享途径的研究可以为子宫内膜异位症治疗靶点提供假设或建议。
